Abstract: Provided are activatable proprotein homodimers, comprising at least two separate polypeptide chains, each chain comprising an IL-2 protein variant that has reduced binding affinity to wild-type IL-2R? relative to that of the wild-type IL-2 sequence, a cleavable linker, and an IL-2 binding protein, among other optional features, and related pharmaceutical compositions and methods of use thereof.